Cormorant Asset Management, LP Eye Point Pharmaceuticals, Inc. Transaction History
Cormorant Asset Management, LP
- $1.3 Billion
- Q2 2024
A detailed history of Cormorant Asset Management, LP transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 8,325,000 shares of EYPT stock, worth $101 Million. This represents 5.57% of its overall portfolio holdings.
Number of Shares
8,325,000
Previous 6,893,235
20.77%
Holding current value
$101 Million
Previous $142 Million
49.17%
% of portfolio
5.57%
Previous 8.2%
Shares
5 transactions
Others Institutions Holding EYPT
# of Institutions
163Shares Held
58.2MCall Options Held
224KPut Options Held
1.41M-
Suvretta Capital Management, LLC New York, NY5.18MShares$62.7 Million1.88% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$45.6 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.65MShares$44.2 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.59MShares$43.5 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.77MShares$33.6 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $413M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...